Britain and America have reached a major commercial pact that will guarantee zero import taxes on UK pharmaceutical shipments going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to boost expenditure on drugs through the public health system. This pledge secures that duties on these key goods will remain at nothing for a period of three years.
This development follows previous warnings to hike import taxes on patented drug products, with figures discussed reaching 100%.
"This agreement with the Britain strengthens the global environment for innovative medicines and introduces much-needed equity to American-British medicine commerce," an announcement noted.
Economic Significance
Medicines constitute one of the Britain's most significant exports to the America, which is easily the biggest buyer for major British pharmaceutical firms.
Export figures reveal that in the year to the end of September, the UK shipped drugs valued at £11.1bn to the US. This figure made up 17.4% of British export trade in that span.
"This deal secures work, increases capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," a minister commented.
Specific UK Commitments
The agreement involves several notable commitments from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to double total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must return to the NHS to stay within budget will be limited at fifteen percent. Previously, repayments exceeded twenty percent.
Broader Context
The deal comes amid a long-running tension between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
The disagreement were intensified by arguments that American consumers were paying a premium for the same drugs than consumers in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a share of its overall budget over the past decade.
